

The Essential Biodata Life Science Partner in Rare and Neurodegenerative Diseases

CENTOGENE (CNTG) Company Presentation
August 2022



Disclaimer

This presentation has been prepared by CENTOGENE N.V. (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the delivery of this presentation at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology, such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any independent source.

For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2020, on Form 20-F filed with the SEC on March 31, 2022, and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

CENTOGENE @ a glance




- Headquarters **Rostock, Germany** with locations in **Boston, MA, Berlin, Germany,** and **Rotkreuz, Switzerland**
- **~500 employees**
- Listed on **Nasdaq** in November 2019 (Ticker: CNTG)



- **FY2021 revenues of €43.5 million**
- Guidance* 2022:
 - **Revenues of ~ €50 - €52 million**
 - YoY growth 15-20%



- **CENTOGENE Biodatabank**, the **world's largest real-world data repository** for rare and neurodegenerative diseases
- State-of-the-art **genomics and multiomics reference lab** (ISO, CAP, & CLIA certified)



- **>50 collaborations with biotech/biopharma partners**, covering over **46 rare diseases**
- **Market access and expansion, clinical development, target and drug screening**

Our ambition is to be the essential biodata life science partner in rare and neurodegenerative diseases

Fueling revenues, growing CENTOGENE Biodatabank, and building biopharma partnerships

3 STRATEGIC PILLARS

1 DIAGNOSTICS

Highly differentiated testing portfolio

Easy logistics via CentoCard & CentoCloud

WES/WGS

Multiomics

Network of ~29,000 active physicians

2 CENTOGENE BIODATABANK

Fuel CENTOGENE Biodatabank with biomaterial, multiomics, as well as clinical data

Productize CENTOGENE Biodatabank (data monetization)

3 BIOPHARMA PARTNERSHIPS

MARKET ACCESS & EXPANSION

Real world Registry

Early Access Programs

Patient Stratification, Genetic & Biomarker Profiling, Modelling

Patient Identification & Diagnostics

CLINICAL DEVELOPMENT

Observational Studies (e.g., epidemiology, patient finding, genetic & biomarker profiling)

POC/ Ph II/III:

Patient Multiomic Profiling, Stratification, Modelling, Efficacy Marker

Patient Identification & Diagnostic

TARGET & DRUG SCREENING

Patient-derived Cell Models & Multiomics

Biomarker/ Assay Identification & Validation

CENTOGENE BIODATA NETWORK (Insight Reports & Biodata licenses)


The Breadth and Depth of CENTOGENE's Biodatabank make it a Unique Resource

>**680,000** individuals
>**30,000** via clinical studies

>**400,000** biosamples from
>**120** countries

Nearly **30,000** active physicians
in our network

>**2,500** rare diseases
diagnosed



>**13k** families with trio analysis

>**31 million** unique variants

High share of pediatric cases

~**50%** of individuals with broad
research consent

**Clinical
Diagnostics**


**Market Access
& Expansion**

**Clin. Development
Support**

**Target & Drug
Screening**

Metrics per March 31, 2022. *Active defined as contact with CENTOGENE within the last 5 years, respectively.

CENTOGENE Biodatabank: the world's largest real-world data repository for rare and neurodegenerative diseases



6 Metrics per March 31, 2022. Active Physicians defined as contact with CENTOGENE within the last 5 years, respectively.

CENTOGENE Pharma Product List - Our ambition is to be the essential biodata life science partner in rare and neurodegenerative diseases

Target & Drug Screening

Patient-derived Cell Models & Multiomics

Biomarker/Assay Identification & Validation

Clinical Development

Observational Studies

Observational Studies
(e.g., epidemiology, patient finding, genetic & biomarker profiling)

POC/ Ph II/III

Patient Multiomic Profiling, Stratification, Modelling, Efficacy Marker

Patient Identification & Diagnostics

Market Access & Expansion

RW Registry & Early Access Programs

Patient Stratification, Genetic & Biomarker Profiling, Modelling

Patient ID & Diagnostics

CENTOGENE Biodata Network

Insight Reports
(e.g., new and existing reports, clinical, genetic, epidemiology)

Biodata Licenses



Market access and expansion: maximize access and personalise patient, provider and biopharma value

Market Access and Expansion



- Real world registry
- Early access programs
- Patient Stratification
- Genetic and Biomarker Profiling
- Modelling
- Patient Identification
- Patient Diagnostics
- CENTOGENE Biodata Network
 - Insight Reports & Biodata Licenses



- 2015 - Ongoing
- **Rare Metabolic and Rare Neurodegenerative Diseases**
- **Provide diagnostic testing services** to identify patients with **rare metabolic and rare neurodegenerative diseases**
- **42 Countries**



- 2015 - Ongoing
- **Hereditary transthyretin amyloidosis (hATTR) disease**
- Sponsored testing program with > 600 samples from 10 countries (Europe) & 125 samples (U.S.)



- 2019 - Ongoing
- **Duchenne muscular dystrophy (DMD)**
- **DMD Sponsored testing program (250 samples)**
- **5 countries:** UAE, KSA, Lebanon, Kuwait, Egypt



- 2019 - Ongoing
- Identify patients in **DMD & Aromatic L-amino Acid Decarboxylase (AADC)**
- **Genetic testing and biomarker analytics** for AADC deficiency in **65 countries** (LATAM, Europe, MENA)
- >2500 DMD & >2900 AADC samples screened

Clinical development: accelerate and expand biopharma partnerships

Clinical Development



Observational studies

- Epidemiology & Patient finding
- Genetic & biomarker profiling

POC/Ph II/III

- Patient multiomic profiling
- Stratification, Modelling, and Efficacy markers
- Patient identification & diagnostics

CENTOGENE Biodata Network

- Insight Reports & Biodata Licenses



- **2021**
- **Hypophosphatasia (HPP)**
- Strensiq (innovative enzyme replacement therapy)
- **De novo variant identification** for HPP and **identification of potential new genes** causing HPP
- **Germany**



- **2018 - Ongoing** (ROPAD 1 & 2 Study with extensions)
- **Parkinson's disease (PD)**
- **Enroll and genotype 12,500 patients**
- **10 countries**
- Success milestone: **10,000 patients enrolled and genotyped**



- **2018 - 2021**
- **Gaucher disease**
- **Longitudinal natural history study** (LysoProof) with **>1,600 samples analyzed**
- **13 countries** (EU, LATAM, APAC, MENA)
- **Identified and genetically tested >250 Gaucher patients**



- **2021 - Ongoing**
- **Pyruvate kinase ("PK") deficiency**
- **Genetic testing and identification of causative mutations**, incl. HBA1, HBA2, and HBB genes, in Ph. II/III trials
- **20 Countries** (North America, Europe, MENA, APAC, & LATAM)



- **2020 - Ongoing**
- **Hereditary transthyretin-related amyloidosis (hATTR)**
- **Longitudinal study providing a molecular genetic diagnosis of hATTR** via NGS and MLPA
- **Germany**
- **5,000 patients enrolled**



- **2021 - Ongoing**
- **Frontotemporal dementia (FTD)**
- **Enroll and genetically test over 3,000 FTD patients in EFRONT Study**
- **7 countries** (Belgium, Germany, Greece, Italy, Portugal, Spain, and Turkey)

Target & drug screening: build partnerships around precision and confidence

Target and Drug Screening



Target & Drug Screening

- Patient-derived cell models & multiomics
- Biomarker/Assay identification & validation

CENTOGENE Biodata Network

- Insight Reports & Biodata Licenses



- **2021 - Ongoing**
- **Niemann-Pick type C**
- **Collaboration to generate data set to enable start of drug discovery**



- **2020 - Ongoing**
- **Gaucher Disease – joint drug discovery project**
- **Joint drug discovery project to identify small molecules reducing biomarker Lyso-GB1 in disease cell models**
- **Transcriptomic and metabolomic data set enabling patient selection with highest unmet need**




- **2021 - Ongoing**
- **Friedreich's Ataxia, Duchenne Muscular Dystrophy, Hereditary transthyretin-related amyloidosis**
- **Novel biomarker discovery to stratify and monitor patients for disease severity/progression and to enable the discovery of disease modifiers explaining heterogeneity**



- **2018 - Ongoing**
- **Rare neurodegenerative diseases**
- **Data Access and Collaboration Agreement granting access to CENTOGENE's Biodatabank for discovery & validation of novel genetic and biochemical targets for the potential development of new therapies for rare diseases**

We have knowledge on a broad footprint of over 2,500 rare and neurodegenerative diseases to deepen scientific understanding and support breakthrough therapies




Our genetic Parkinson's disease dataset is unique in depth and breadth

Existing data and biomaterial can support work on diagnosis, disease progression, and treatment



~10,500 research consented individuals + Controls

CENTOGENE Biodatabank



Multiomic Data

Whole Genomes, Variants, Biomarker, Enzymatic Activity

Clinical Data

Symptoms (HPO), Medication, History, MDS-UPDRS Neuro Test, Age of Onset

Biomaterial

Dried Blood Spots Cards

Sociodemo-graphic information

Gender, Age, Geography, Ethnicity, Family History


Target & Drug Screening

Clinical Trial Support

Market Access & Expansion

First-class data capture and proprietary curation and analysis technologies established the CENTOGENE Biodatabank to predict, accelerate, and personalize treatment

Data capture



Central collection and storage of biosamples
from >120 countries



Clinical data capture



Clinical data extraction & curation



Whole genome sequencing



State-of-the-art mass spectrometry



RNA sequencing

Data bioinformatics



Automated pipelines for

- variant annotation
- prioritization
- medical reporting
- > 31 million variants
- multiomic analysis and combination expertise

Data utilization

Clinical Diagnostics

Biopharma Partnerships

Target & Drug Screening

Clinical Development Support


Market Access & Expansion

Value chain supported by advanced bioinformatics and AI tools


Diagnostics: A distinctive offering and services that support efficient and timely diagnosis of rare and neurodegenerative diseases, leading to better treatment and health outcomes

Highly differentiated testing portfolio in state-of-the-art CLIA/CAP certified laboratory with **deep medical expertise**



Exome testing



Genome testing



Multiomic testing



Easy logistics for centralized testing enabling **broad access to multiomics**



Dry-lab (SaaS) solution enabling laboratories around the world to deliver leading diagnostic **insights to local patients**



Unique global footprint with **network of ~29,000 active physicians** and **focus on countries with a high prevalence of rare diseases**

We have leading, differentiated core products that drive definitive diagnosis for the benefit of patients & fuel our biodatabank enabling greater understanding of diseases

LAUNCHED
JUNE 2021

Centoxome®

LAUNCH
March 2022

≥ 98% of the exome at ≥ 20x
~20,000 genes

MOx

~8,000
clinical genes

Non-coding pathogenic variants

HGMD® ClinVar

CENTOGENE

Mitochondrial genome

37 genes

Centometabolic MOx

≥ 99.5% targeted regions covered at ≥ 20x

206 genes

180
Inherited metabolic disorders

Clinically relevant variants

HGMD®

CENTOGENE

20 enzymes and biomarkers

Centogenome

LAUNCH
March 2022

≥ 97% of the genome at ≥ 10x
>20,000 genes

MOx

Complete genome map in
1 single test

Coding and non-coding regions

Mitochondrial genome

37 genes

NGS Panels

≥ 99% targeted regions covered at ≥ 20x

16
disease categories

Single Nucleotide Variants

HGMD®

CENTOGENE

Mitochondrial genome

Auxiliary assays

Quality, data integrity & privacy are core to CENTOGENES business processes, driven by first-class data capture, multi-level QMS, & proprietary curation

CENTOGENE follows the strictest quality criteria to meet our customer's requirements in clinical diagnostics, clinical trial services and research & development. CENTOGENE's QMS integrates into every aspect of our operations, from data integrity and privacy, patient safety, and responsibility to scientific research and innovations.

- CENTOGENE's **holistic quality management system (QMS)** has been recognized by **our CAP, CLIA, and ISO 15189 certifications**. CENTOGENE's biobank is the first CAP accredited repository outside the U.S., compliant with ISO 20387
- As a full service company - we follow applicable and market-standard **good laboratory practice (GLP)** and **good manufacturing practice (GMP)** guidelines
- We continually participate in the **international external proficiency testing schemes** of the **European Molecular Genetics Quality Network (EMQN)** and the **College of American Pathologists (CAP)** to ensure technical and medical competency and proficiency
- CENTOGENE's **processes and IT systems are ISO/IEC 27001:2017 certified** by the independent accreditor datenschutz cert GmbH, ensuring a high level of confidentiality, availability, and integrity to all processed data
- **CentoPortal is certified for providing safety and privacy** according to the "internet privacy standards" by German accreditor datenschutz-cert



Rostock Lab #8574447 (biorepository)
Boston Lab #8417628



#99D2049715
#22D2154474



Certificate-ID: DSC.843.09.2020



CENTOGENE



Urkunden-ID: DSC.1096.11.2021

A unique diagnostic portfolio of products, technologies, and enablers

PRODUCTS

CentoCard®
Unique and proprietary CE-labeled DBS sample collection kit

CentoCloud®
Cloud-based automated bioinformatics and medical reporting solution

CentoXome®
Enhanced WES with uniform coverage across the entire exome and increased Dx yield of up to 20%*

CentoGenome®
Advanced WGS solution capturing one of the most extensive ranges of disease-causing genetic variants

MOx Products
Multiomic WES/WGS/Panel solutions integrating NGS w/ biochemical analysis to provide a complete clinical picture (e.g. CentoMetabolic®)

TECHNOLOGY

Logistics

SaaS**

NGS**

NGS

**Multomics/
Biomarkers**

ENABLERS

Physician network

- Nearly 30,000 active physicians worldwide
- Composed of a range of specialties, with emphasis on neurology


Reports & Genetic Counselling

- Proactive, free-of-charge reclassification program
- Access to a network of genetic counsellors and liaisons enables better diagnostics, interpretation and physician counselling

Accreditations

- CAP accredited
- CLIA accredited
- ISO 15189 certified
- CAP accredited Biobank, compliant with ISO20387

We are an essential partner across Biopharma for diagnosing, understanding, and treating rare and neurodegenerative diseases



Pharma partnerships - The opportunity: By 2024, 18% of Rx worldwide will be for rare diseases

Rare diseases

CENTOGENE Biodatabank

Largest WW biorepository for rare diseases*

- Estimated 80% of ~7,000 rare diseases are genetic in origin: ~5,600¹
- CENTOGENE Biodatabank covers >2,500 diseases²
- Public datasets are ~80% of European descent⁷
- CENTOGENE database rich in bio samples, ethnic diversity and patient consent

Rare disease market


- Rare diseases market expected to grow 11+% to 2024³
- By 2024 rare disease products account ~18% R sales⁴
- FDA have approved 23 gene/cell therapies to date⁵
- >50% of FDA approvals in 2021 were orphan drugs⁶

Regulatory and payor scrutiny*

- RD, NDD and gene therapies are typically premium price products with high unmet need and patient pressure
- Regulatory/payor scrutiny will raise standards for approval, access and entry
- Patient profiling/stratification can help to improve labelling/pricing optimization and probability of success

CENTOGENE 2021 Financials

Core Business - Dx and Biopharma revenues¹



Record year for Diagnostics

Diagnostics

- Full year 27.9 € million +26% vs FY 2020
- 57,000 test requests +36% vs FY 2020
- WES and WGS ~ 20 € million +25% vs FY 2020

Impacted by COVID

Biopharma

- Full year 15.6 € million -8% vs FY 2020
- Q4 revenues 6.5 € million +40% YoY
- 45 active collaborations by end 2021
- Driven by partnerships in patient identification and clinical development


CENTOGENE Q1 2022 Financials

Dx and Biopharma revenues in € million¹

Double-digit growth rate

Diagnostics

- Q1 2022 €7.1 million +11% vs Q1 2021
- Q1 2022 16,300 test requests +24% vs Q1 2021
- WES and WGS ~ 3.7 € million +18% vs Q1 2021
- Product portfolio updates on CentoCloud & MOx



Longer recovery post COVID impact

Biopharma

- Q1 2022 € 3.2 million, -10% vs Q1 2021
- Primarily attributable to impact of COVID-19 on slowing pharma programs and longer sales cycle
- 42 active collaborations per March 31, 2022
- Post Q1 2022 extended Agios & Takeda contracts



CENTOGENE Q1 2022 Financials

P&L and balance sheet highlights in € million¹

	Q1 2021	Q1 2022	delta
Revenue	10.0	10.3	+0.3
Cost of sales	6.2	6.5	+0.3
Gross Profit	3.8	3.9	+0.1
Gross Profit %	38%	38%	-
Research & development expenses	4.3	4.6	+0.3
General Administrative expenses	11.6	7.9	(3.7)
Selling expenses	1.9	2.4	+0.5
Impairment of financial assets	0.1	0.2	+0.1
Other operating income	0.4	0.7	+0.3
Other operating expenses	0.0	0.0	-
Operating loss	(13.9)	(10.5)	+3.4

Balance sheet highlights (in € million)


	Q1 2022	Q4 2021	delta
Cash & cash equivalents	42.7	17.8	24.8
Debt outstanding ²	(43.0)	(22.5)	(20.5)
Net debt	(0.3)	(4.7)	4.4

22 1 Selected information, may include rounding differences

2 Debt outstanding includes non-current loans, non-current lease liabilities, current loans and current lease liabilities.

CENTOGENE Guidance: 2022 poised for post-COVID recovery and refocus on core business and growth strategy

Core Business - Dx and Biopharma revenues¹



FY 2022 Guidance²



- **\$62 million financing (~€55 million)** announced Q1 2022:
 - €15 million PIPE & \$45 million debt³
- Q1 of € 10.3 million up 3% year-over-year - acceleration in second half driven by biopharma
- Q1 COVID-19 revenues of ~€19 million; exited in **Q1 2022⁴**

CENTOGENE 2022 Priorities: Focus on growth, execution, fit-for-purpose organization



Meet/Exceed Revenues Guidance

- 50-52 € million total revenues
- ~15-20% growth y-o-y



Fuel Biopharma Partnerships

- Fully execute on our existing >20 ongoing partnerships
- Target ~20+ new pipeline deals



Optimize Dx Revenues Growth

- Focus on profitable growth
- Commercial excellence, CentoCloud & multiomics



Fit-for-Purpose Organization

- Drive fit-for-purpose organization
- Focus on efficient operations and margin improvement

Thank you

To our investors

To our partners

To our associates

MISSION

Together let's cure
100 rare diseases
(and others) in the
next 10 years

